OverviewSuggest Edit
Alector is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.
| Type | Public | |
| Founded | 2013 | |
| HQ | South San Francisco, CA, US | Map |
| Website | alector.com |
Recent NewsAll News
- Alector Provides 2021 Corporate Portfolio Update
- Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
- Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia
- Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
Key People/Management at Alector
Arnon Rosenthal
Spencer LIang
Shehnaaz Suliman
Robert King
Sabah Oney
Robert Paul
Alector Office Locations
Alector Financials and Metrics
Alector Revenue
| USD | |
|---|---|
Revenue (Q2, 2020) | 3.2m |
Net income (Q2, 2020) | (45.3m) |
EBIT (Q2, 2020) | (46.6m) |
Market capitalization (14-Jan-2021) | 1.2b |
Closing stock price (14-Jan-2021) | 15.5 |
Cash (30-Jun-2020) | 92.5m |
EV | 1.2b |
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (8.4m) | (19.6m) | (34.9m) | (18.6m) | (43.1m) | (74.9m) | (40.0m) | (85.3m) |
Depreciation and Amortization | 212.0k | 464.0k | 743.0k | 298.0k | 1.1m | 2.4m | 1.4m | 2.9m |
Accounts Payable | (783.0k) | (830.0k) | (604.0k) | 683.0k | 414.0k | 132.0k | 3.1m | 4.4m |
Cash From Operating Activities | 184.5m | 167.5m | 145.1m | (23.6m) | (41.6m) | (70.5m) | (32.3m) | (78.3m) |
| USD | FY, 2017 |
|---|---|
Financial Leverage | -4.5 x |
Alector Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Alector LLC |
Alector Revenue Breakdown
Alector revenue breakdown by business segment: 100.0% from Collaboration
Alector Cybersecurity Score
Alector Environment, Social & Governance (ESG) Ratings
Alector Online and Social Media Presence
Alector's Trends
Alector News and Updates
Alector Provides 2021 Corporate Portfolio Update
Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
What Kind Of Shareholder Owns Most Alector, Inc. (NASDAQ:ALEC) Stock?
Analysts Have Made A Financial Statement On Alector, Inc.'s (NASDAQ:ALEC) First-Quarter Report
Alector Frequently Asked Questions
When was Alector founded?
Alector was founded in 2013.
Who are Alector key executives?
Alector's key executives are Arnon Rosenthal, Spencer LIang and Shehnaaz Suliman.
How many employees does Alector have?
Alector has 126 employees.
What is Alector revenue?
Latest Alector annual revenue is $21.2 m.
What is Alector revenue per employee?
Latest Alector revenue per employee is $168.4 k.
Who are Alector competitors?
Competitors of Alector include Verge Genomics, Encoded Therapeutics and NKMax.
Where is Alector headquarters?
Alector headquarters is located at 131 Oyster Point Blvd #600, South San Francisco.
Where are Alector offices?
Alector has offices in South San Francisco and Milpitas.
How many offices does Alector have?
Alector has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies